Last reviewed · How we verify
TH07
TH07 is a small molecule that targets the androgen receptor.
TH07 is a small molecule that targets the androgen receptor. Used for Prostate cancer, Androgenetic alopecia.
At a glance
| Generic name | TH07 |
|---|---|
| Sponsor | Triple Hair Inc |
| Drug class | Androgen receptor inhibitor |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the androgen receptor, thereby inhibiting its activity. This leads to a decrease in the production of androgen-dependent proteins, which can contribute to various diseases.
Approved indications
- Prostate cancer
- Androgenetic alopecia
Common side effects
- Fatigue
- Hypertension
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TH07 CI brief — competitive landscape report
- TH07 updates RSS · CI watch RSS
- Triple Hair Inc portfolio CI